The Paradox of Healthcare in the ‘Superbugs’ Era: Current Challenges and Future Directions

Antibiotic-resistant microbes represent a growing problem for modern medicine and public health. Projections indicate that deaths from such infections could reach 10 million per year by 2050. Healthcare associated infections (HAI) are among the most significant causes of mortality and morbidity in hospitals, impacting millions of patients globally. The emergence of HAI is associated with resistance to antimicrobials, rapidly worsening the patient's condition. Antimicrobial resistance determines unresponsiveness to treatment, which can ultimately lead to severe complications such as sepsis and shock. It is estimated that one in every ten patients are susceptible to infection during their stay in hospital, with the microorganism responsible for the infection frequently proving resistant to antibiotics. Among the latter, CRE (carbapenem-resistant <i>Enterobacteriaceae</i>), CRAB (carbapenem-resistant <i>Acinetobacter baumannii</i>), CRPA (carbapenem-resistant <i>Pseudomonas aeruginosa</i>), vancomycin-resistant <i>Enterococcus</i> spp. and methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), commonly referred to as 'superbugs', are a major cause of HAIs. The aim of the present study is to provide a comprehensive overview of the global epidemiology of healthcare-associated infections, with particular emphasis on their incidence, distribution over time, and correlation with the socioeconomic status of different countries. Furthermore, the review aims to evaluate the effectiveness of current preventive strategies in reducing the incidence and mortality associated with HAIs.